Adagene Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 10, 2021 / 06:00PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director

Great. Good afternoon, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Adagene with us for the next session.

Before we get started, I need to read a quick disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/research disclosure.

So with that, pleased to introduce Peter Luo, the CEO of Adagene. And Peter, I know you want to make some opening comments, so I'll turn it over to you for that. And then we can get into Q&A.

Peter P. Luo - Adagene Inc. - Co-Founder, CEO & Chairman of the Board

Thanks, Matthew. And thanks, everyone, for your time. And today, I'd like to take this opportunity to walk you through a few highlights about Adagene.

And here the investment highlights, I'd like to walk you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot